Understanding the Latest in GLP-1 Agonists: Insights from the Docs Who Lift Podcast

In a recent episode of the Docs Who Lift Podcast, hosts Dr. Spencer Nadolsky and Dr. Carl discussed the anticipated results from the Surmount 5 trial, which compared two significant GLP-1 agonists: tepati (Zepbound) and semaglutide (Wegovy). They also dove into the implications of these results for obesity treatment and the ongoing discussions around compounded versions of these medications.

Key Findings from the Surmount 5 Trial

The Surmount 5 trial aimed to assess the efficacy of tepati against semaglutide specifically in individuals with obesity but without type 2 diabetes. While the detailed publication of the study is forthcoming, the topline results indicated:

A significant weight loss average of 20% for the tepati group compared to 14% for the semaglutide group.
In the previous trials, participants with type 2 diabetes showed a weight loss of 7% with semaglutide, while those on tepati achieved up to 13.3% weight loss depending on dosage.
Weight loss of 10% or more is crucial for clinical improvement in metabolic health.

Cardiorenal Protection and GLP-1 Agonists

The discussion also highlighted the cardiorenal protective benefits of GLP-1 agonists, with a meta-analysis showing a significant reduction in major cardiovascular events and kidney complications among patients receiving these medications. Key statistics included:

18% reduction in composite kidney outcomes.
13.3% reduction in major cardiovascular outcomes.
No statistically significant increase in pancreatitis risk associated with the drugs.

The Risks of Compounded GLP-1 Agonists

Dr. Nadolsky and Dr. Carl expressed concerns about the rising trend of compounded GLP-1 agonists. The American Diabetes Association (ADA) recently issued a statement discouraging the use of non-FDA approved compounded incretin products due to uncertainties regarding their safety, quality, and effectiveness.

Key points from the ADA statement included:

Compounded medications should not be used due to safety concerns.
Patients should switch to FDA-approved medications on an individual basis when available.

Conclusion

The results from the Surmount 5 trial are promising for the future of obesity treatment with GLP-1 agonists. However, the risks associated with compounded versions and the need for comprehensive care cannot be overlooked. As the landscape of obesity treatment evolves, it remains crucial for individuals to seek appropriate medical guidance to ensure safe and effective care.

Key Takeaways:

The Surmount 5 trial showed significant weight loss for both GLP-1 agonists in obese patients.
GLP-1 agonists provide cardiorenal protection and show promise in reducing major health risks.
The ADA advises against the use of compounded GLP-1 medications due to safety concerns.
Comprehensive patient care is essential when considering GLP-1 therapies.

The hosts of the podcast include Dr. Spencer Nadolsky and Dr. Carl, both of whom are well-versed in the latest developments in obesity treatment and metabolic health.